• Promega places new order as EXO-NET customer base expands globally
• INOVIQ advances AI-enhanced algorithms for EXO-OC ovarian cancer screening test
• Peter Mac engaged to validate INOVIQ's CAR-exosome therapy for TNBC

INOVIQ Limited (ABN 58 009 070 384) has provided a quarterly business update and Appendix 4C for the period ending March 2025. Key highlights include: Exosome Programs Advanced - EXO-NET customer base expanded globally, with Promega placing a new order. INOVIQ advanced the development of AI-enhanced machine learning algorithms for its EXO-OC ovarian cancer screening test. INOVIQ also engaged the Peter MacCallum Cancer Centre to further validate its CAR-exosome therapy for triple negative breast cancer (TNBC). neuCA15-3 Diagnostic Performance Published - INOVIQ's scientific paper on the neuCA15-3 breast cancer monitoring test was accepted for publication in the international peer-reviewed journal Breast Cancer Research and Treatment. Medical and Scientific Advisory Board Formed - INOVIQ established a Medical and Scientific Advisory Board to provide expert guidance on its diagnostic and therapeutic programs. New Chief Commercial Officer Appointed - Dr Emma Ball was appointed as Chief Commercial Officer to lead commercialization efforts. Financial Results - INOVIQ had a cash balance of $8.012 million at 31 March 2025, with operating cash outflows of $1.455 million for the quarter.